Dapagliflozin Is A New Drug For The Treatment Of Type Two Diabetes – Part 1 of 3
Dapagliflozin Is A New Drug For The Treatment Of Type Two Diabetes. A renewed drug, the first in its class, gives added blood sugar direction to people with type 2 diabetes who are already taking the glucose-lowering medication metformin. The new agent, dapagliflozin, which also helped patients lose weight, is novel in that it does not work as the crow flies on the body’s insulin mechanisms, according to a study appearing in the June 26 issue of The Lancet and slated for presentation at the annual meeting of the American Diabetes Association (ADA) in Orlando. “It will as likely as not be used as an add-on therapy,” said study lead author Clifford Bailey, a chemical pathologist and professor of clinical science at Aston University in Birmingham, UK “If you don’t unequivocally get to target with the first therapy tried, this approach would offer you an opportunity hopefully to maintain improved control”.
Bailey, who could not predict if or when the drug might get final approval from drug regulatory authorities, also keen out that dapagliflozin is flexible, meaning it can be used with various other treatments and at more or less any stage in the disease. “It’s a good add-on,” agreed Dr Stanley Mirsky, associate clinical professor of metabolic diseases at Mount Sinai Medical Center in New York City. “Is it a ponder drug? No. It may play a small role”.
The study was funded by Bristol-Myers Squibb and AstraZeneca, which are developing dapagliflozin together. Dapagliflozin shop by stimulating the kidneys to eliminate more glucose from the body via urine. In this study of 534 adult patients with type 2 diabetes who were already taking metformin, the highest amount of dapagliflozin (10 milligrams daily) was associated with a 0,84 percent decrease in HbA1c levels.